Predictors of Long-Term Survival among High-Grade Serous Ovarian Cancer Patients

被引:19
|
作者
Clarke, Christina L. [1 ]
Kushi, Lawrence H. [2 ]
Chubak, Jessica [3 ]
Pawloski, Pamala A. [4 ]
Bulkley, Joanna E. [5 ]
Epstein, Mara M. [6 ,7 ]
Burnett-Hartman, Andrea N. [1 ]
Powell, Bethan [8 ]
Pearce, Celeste L. [9 ]
Feigelson, Heather Spencer [1 ]
机构
[1] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA
[2] Kaiser Permanente Northern Calif, Div Res, Oakland, CA USA
[3] Kaiser Permanente Washington, Hlth Res Inst, Seattle, WA USA
[4] HealthPartners Inst, Bloomington, MN USA
[5] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA
[6] Meyers Primary Care Inst, Worcester, MA USA
[7] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA USA
[8] Kaiser Permanente Northern Calif, Gynecol Oncol Program, San Francisco, CA USA
[9] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA
关键词
D O I
10.1158/1055-9965.EPI-18-1324
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Relatively little is known about factors associated with long-term survival (LTS) following a diagnosis of ovarian cancer. Methods: We conducted a retrospective study of high-grade serous ovarian cancer (HGSOC) to explore predictors of LTS (defined as >= 7 years of survival) using electronic medical record data from a network of integrated health care systems. Multivariable logistic regression with forward selection was used to compare characteristics of women who survived >= 7 years after diagnosis (n = 148) to those who died within 7 years of diagnosis (n = 494). Results: Our final model included study site, age, stage at diagnosis, CA-125, comorbidity score, receipt of chemotherapy, BMI, and four separate comorbid conditions: weight loss, depression, hypothyroidism, and liver disease. Of these, only younger age, lower stage, and depression were statistically significantly associated with LTS. Conclusions: We did not identify any new characteristics associated with HGSOC survival. Impact: Prognosis of ovarian cancer generally remains poor. Large, pooled studies of ovarian cancer are needed to identify characteristics that may improve survival.
引用
收藏
页码:996 / 999
页数:4
相关论文
共 50 条
  • [31] High-grade serous ovarian cancer: the clone wars
    Aleksander Salomon-Perzyński
    Magdalena Salomon-Perzyńska
    Bogdan Michalski
    Violetta Skrzypulec-Plinta
    Archives of Gynecology and Obstetrics, 2017, 295 : 569 - 576
  • [32] High-grade serous ovarian cancer: the clone wars
    Salomon-Perzynski, Aleksander
    Salomon-Perzynska, Magdalena
    Michalski, Bogdan
    Skrzypulec-Plinta, Violetta
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2017, 295 (03) : 569 - 576
  • [33] The role of Apela in high-grade serous ovarian cancer
    Daily, Laura R.
    Ganguly, Debolina
    Hayes, D. Neil
    Wang, Yinan
    Sims, Michelle M.
    Cheng, Jinjun
    ElNaggar, Adam C.
    Pfeffer, Lawrence M.
    CANCER RESEARCH, 2018, 78 (13)
  • [34] Drugs Repurposing in High-Grade Serous Ovarian Cancer
    Torralba, Manuel
    Farra, Rossella
    Maddaloni, Marianna
    Grassi, Mario
    Dapas, Barbara
    Grassi, Gabriele
    CURRENT MEDICINAL CHEMISTRY, 2020, 27 (42) : 7222 - 7233
  • [35] The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer
    van Baal, J. O. A. M.
    Van de Vijver, K. K.
    Algera, M. D.
    van Der Aa, M. A.
    Sonke, G. S.
    van Driel, W. J.
    Kenter, G. G.
    Amant, F. C.
    Lok, C. A. R.
    GYNECOLOGIC ONCOLOGY, 2019, 153 (03) : 562 - 567
  • [36] A gene expression prognostic signature for overall survival in patients with high-grade serous ovarian cancer.
    Millstein, Joshua
    Budden, Timothy
    Anglesio, Michael
    Talhouk, Aline
    Beeghly-Fadiel, Alicia
    Berchuck, Andrew
    Chenevix-Trench, Georgia
    deFazio, Anna
    Fasching, Peter A.
    Gayther, Simon
    Garcia, Maria
    Goode, Ellen L.
    Henderson, Michelle
    Konecny, Gottfried E.
    Orsulic, Sandra
    Huntsman, David
    Bowtell, David
    Doherty, Jennifer
    Pharoah, Paul
    Ramus, Susan J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [37] The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer
    van Baal, J.
    Van de Vijver, K.
    Algera, M.
    van der Aa, M.
    Sonke, G.
    van Driel, W.
    Kenter, G.
    Amant, F.
    Lok, C.
    VIRCHOWS ARCHIV, 2019, 475 : S88 - S88
  • [38] THE EFFECT OF ADJUVANT CHEMOTHERAPY ON SURVIVAL IN PATIENTS WITH FIGO STAGE I HIGH-GRADE SEROUS OVARIAN CANCER
    van Baal, J.
    Van de Vijver, K.
    van der Aa, M.
    Sonke, G.
    van Driel, W.
    Kenter, G.
    Amant, F.
    Lok, C.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 756 - 757
  • [39] Elucidating mechanisms involved in long-term response to platinum-based chemotherapy in high-grade serous ovarian cancer.
    Lheureux, Stephanie
    Yang, Cindy
    Shaw, Patricia
    Clarke, Blaise
    Tsao, Julissa
    Karakasis, Katherine
    Butler, Marcus
    Salman, Noor
    Dowar, Mark
    Xu, Jing
    Poulain, Laurent
    Ohashi, Pamela S.
    Pugh, Trevor
    Oza, Amit
    CLINICAL CANCER RESEARCH, 2016, 22
  • [40] Disparities in treatment modalities and survival among elderly high grade serous ovarian cancer patients
    Shu, Tong
    Cai, Yan
    Zheng, Hong
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A172 - A172